CEMIP (cell migration inducing protein, hyaluronan binding )

2013-10-01   Nikki Ann Evensen  , Cem Kuscu  , Jian Cao  

Stony Brook University, Stony Brook, New York, USA

Identity

HGNC
LOCATION
15q25.1
LOCUSID
ALIAS
CCSP1,HYBID,KIAA1199,TMEM2L
FUSION GENES

DNA/RNA

Atlas Image

Description

The human KIAA1199 transcript spans 7080 base pairs on chromosome 15 in the region 15q25.1. It contains 29 exons, 28 of which are coding, and 28 introns. The transcriptional start site is within the second exon. There is a canonical TATA-box present in the KIAA1199 promoter region at -31 to -27 base pairs, as well as a GC-box at -248 to -243 base pairs. However, this GC-box was not found to be required for transcriptional activation of KIAA1199, nor was there any methylation of the cytosines found within this region, which is often an important feature of GC-boxes. KIAA1199 also contains a CpG island within the first intron (+525 50 +1025). The methylation status of this CpG island was found to effect the expression level of KIAA1199, with high levels of DNA methylation found in non-aggressive, low expressing, cancer cell lines (Kuscu et al., 2012).

Transcription

An AP-1 binding site, located between -48 and -45 within the KIAA1199 promoter, was found to be important for KIAA1199 promoter activity. AP-1 was found to directly bind to this region in order to activate transcription of KIAA1199. AP-1 transcription factors have been associated with increased promoter activity of genes associated with cancer. Additionally, among four potential NF-κB binding sites, the site furthest from the transcriptional start site (-1345 to -1333) was found to play a role in KIAA1199 promoter activation. NF-κB was found to directly bind to this site to increase transcription of KIAA1199 (Kuscu et al., 2012).

Proteins

Description

The KIAA1199 open reading frame consists of 4083 base pairs, which encodes a protein 1361 amino acids in length. It has a predicted molecular weight of approximately 163 kDa. The KIAA1199 protein has a G8 domain between a.a. 44-166, which is a novel domain that contains eight conserved glycines and consists of five β-strand pairs (He et al., 2006). Several disease related proteins contain this domain, including polyductin protein (PKHD1) and transmembrane protein 2 (TMEM2), although the exact function of the G8 motif remains unclear (He et al., 2006). A GG domain, characterized by seven β-strands and two α-helices, can also be found within the KIAA1199 protein (Guo et al., 2006). This novel domain also has no known function. KIAA1199 is also predicted to have a cleavable signal peptide at its NH2-terminus (Sabates-Bellver et al., 2007). KIAA1199 has been demonstrated to be N-linked glycosylated (Tiwari et al., 2013).

Expression

Northern blot analysis of normal human tissues revealed expression of KIAA1199 mRNA in various tissues, with the highest levels found in the brain, placenta, lung, and testis (Michishita et al., 2006). KIAA1199 is also expressed in various cell types found in the inner ear (Abe et al., 2003; Usami et al., 2008), and in dermal fibroblasts of the skin (Yoshida et al., 2013). Increased levels of KIAA1199 have also been demonstrated in numerous cancer tissues compared to normal tissues, including colorectal adenomas (Sabates-Bellver et al., 2007).

Localisation

Cytoplasmic and nuclear staining for KIAA1199 has been observed in gastric and colon cancer tissue samples (Sabates-Bellver et al., 2007; Matsuzaki et al., 2009; Birkenkamp-Demtroder et al., 2011). More detailed subcellular localization revealed expression of exogenous and endogenous KIAA1199 within the endoplasmic reticulum (ER) of various cell types (Evensen et al., 2013; Tiwari et al., 2013). KIAA1199 was found to interact with the ER chaperone binding immunoglobulin protein (BiP)/glucose-regulated protein (GRP-78), which further supports the ER localization of KIAA1199 (Evensen et al., 2013). Secretion of KIAA1199 has also been demonstrated for certain cell types (Tiwari et al., 2013).

Function

KIAA1199 plays a key role in cancer progression via increasing cancer cell migration and invasion, which are necessary steps for cancer metastasis. Expression of KIAA1199 in non-aggressive cancer cell lines leads to an epithelial-to-mesenchymal transition along with increased migratory capabilites. Furthermore, knockdown of KIAA1199 leads to a loss of mesenchymal characteristics with decreased invasive and migratory abilities, as well as reduced metastastic potential (Evensen et al., 2013).
A role for KIAA1199 in maintaining ion homeostasis, and more specifically calcium signaling, has also been suggested (Abe et al., 2003; Tiwari et al., 2013). KIAA1199-mediated migration was found to involve elevated cytosolic calcium levels followed by protein kinase C alpha (PKCα) translocation/activation. This change in cytosolic calcium is due to increased release of calcium from the ER via an unknown mechanism induced by KIAA1199 (Evensen et al., 2013). Additional studies revealed an interaction with KIAA1199 and inositol 1,4,5-triphosphate receptor 3 (ITPR3) which is a ligand-gated ion channel located on the ER membrane that is known to mediate the release of calcium from the ER (Tiwari et al., 2013).
KIAA1199 is thought to be a target of the Wnt signaling pathway and a potential player in the progression of colorectal adenomatous (Sabates-Bellver et al., 2007; Tiwari et al., 2013). Additionally, silencing of KIAA1199 was shown to alter the expression of genes known to be involved in the Wnt/β-catenin pathway and decrease cell proliferation (Birkenkamp-Demtroder et al., 2011).
In human skin fibroblasts, KIAA1199 expression was found to cause increased degradation of hyaluronan (HA), which is a glycosaminoglycan found in the extracellular matrix surrounding tissues. It acts as a structural component and can affect cell signaling and cellular behavior, including angiogenesis and cell migration (Yoshida et al., 2013).

Homology

The KIAA1199 gene product shares 38% identity (63% similarity) with transmembrane protein 2 (TMEM2). A small region within the KIAA1199 gene product (aa 55-155) also shares 38% identity (57% similarity) with polyductin protein (PKHD1) (Abe et al., 2003). However, none of these homologies revealed any functional information.

Mutations

Somatic

Nine DNA variants of the KIAA1199 gene were identified, six of which were missense (R187C, R187H, H783R, H783Y, V1109I, and P1169A) and three of which were synonymous substitutions (L532L, P619P, D800D). R187C, R187H, H783Y, and V1109I were found only in families with nonsyndromic hearing loss, suggesting a potential role for these specific mutations in this disease state (Abe et al., 2003).

Implicated in

Entity name
Gastric and colorectal cancers
Prognosis
Numerous studies have implicated KIAA1199 expression with cancer progression. Gastric cancer patients with low expression of KIAA1199 were found to have significantly better overall 5-year survival rates as compared to those expressing higher levels. Furthermore, lymph node metastasis, distant metastasis, and peritoneal dissemination were more often observed in the patients with higher levels of KIAA1199 (Matsuzaki et al., 2009).
Additionally, there is evidence to suggest that KIAA1199 could potentially be used as a biomarker for cancer. Higher levels of KIAA1199 transcripts were found in the serum of patients with adenoma and colorectal cancer as compared to neoplasia free controls (LaPointe et al., 2012). KIAA1199 was also found to be upregulated in cancerous tissues from gastric adenocarcinoma patients, further supporting the idea of using KIAA1199 for diagnostics, early detection, or as a predictor of cancer progression (Chivu Economescu et al., 2010).
Entity name
Nonsyndromic hearing loss
Prognosis
Several mutations within KIAA1199 were found in patients with nonsyndromic hearing loss but not in control subjects. Based on the expression pattern of KIAA1199 in the cells of the inner ear, it is thought that it could play a role in normal auditory development with these particular mutations having a negative impact (Abe et al., 2003).

Article Bibliography

Pubmed IDLast YearTitleAuthors
145770022003Mutations in the gene encoding KIAA1199 protein, an inner-ear protein expressed in Deiters' cells and the fibrocytes, as the cause of nonsyndromic hearing loss.Abe S et al
217723342011Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells.Birkenkamp-Demtroder K et al
214431022010Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection.Chivu Economescu M et al
239906682013Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration.Evensen NA et al
164063692006GG: a domain involved in phage LTF apparatus and implicated in human MEB and non-syndromic hearing loss diseases.Guo J et al
166324972006G8: a novel domain associated with polycystic kidney disease and non-syndromic hearing loss.He QY et al
229702802012Transcriptional and epigenetic regulation of KIAA1199 gene expression in human breast cancer.Kuscu C et al
222761022012Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing.LaPointe LC et al
194344582009Clinicopathologic significance of KIAA1199 overexpression in human gastric cancer.Matsuzaki S et al
161574442006Upregulation of the KIAA1199 gene is associated with cellular mortality.Michishita E et al
181719842007Transcriptome profile of human colorectal adenomas.Sabates-Bellver J et al
239360242013Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors.Tiwari A et al
184482572008The localization of proteins encoded by CRYM, KIAA1199, UBA52, COL9A3, and COL9A1, genes highly expressed in the cochlea.Usami S et al
235092622013KIAA1199, a deafness gene of unknown function, is a new hyaluronan binding protein involved in hyaluronan depolymerization.Yoshida H et al

Other Information

Locus ID:

NCBI: 57214
MIM: 608366
HGNC: 29213
Ensembl: ENSG00000103888

Variants:

dbSNP: 57214
ClinVar: 57214
TCGA: ENSG00000103888
COSMIC: CEMIP

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000103888ENST00000220244Q8WUJ3
ENSG00000103888ENST00000356249Q8WUJ3
ENSG00000103888ENST00000394685Q8WUJ3
ENSG00000103888ENST00000495041H0YCE1
ENSG00000103888ENST00000560027H0YL56

Expression (GTEx)

0
10
20
30
40
50
60
70
80
90

Pathways

PathwaySourceExternal ID
MetabolismREACTOMER-HSA-1430728
Metabolism of carbohydratesREACTOMER-HSA-71387
Glycosaminoglycan metabolismREACTOMER-HSA-1630316
Hyaluronan metabolismREACTOMER-HSA-2142845
Hyaluronan biosynthesis and exportREACTOMER-HSA-2142850

References

Pubmed IDYearTitleCitations
381994932024ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT.1
381994932024ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT.1
359977672023CEMIP (HYBID, KIAA1199): structure, function and expression in health and disease.9
365965912023Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation.9
366074782023Downregulation of CEMIP enhances radiosensitivity by promoting DNA damage and apoptosis in colorectal cancer.4
367462612023CEMIP promotes small cell lung cancer proliferation by activation of glutamine metabolism via FBXW7/c-Myc-dependent axis.2
368494602023CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway.2
369316082023CEMIP-mediated hyaluronan metabolism facilitates SCLC metastasis by activating TLR2/c-Src/ERK1/2 axis.1
371967672023Human TMEM2 is not a catalytic hyaluronidase, but a regulator of hyaluronan metabolism via HYBID (KIAA1199/CEMIP) and HAS2 expression.5
359977672023CEMIP (HYBID, KIAA1199): structure, function and expression in health and disease.9
365965912023Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation.9
366074782023Downregulation of CEMIP enhances radiosensitivity by promoting DNA damage and apoptosis in colorectal cancer.4
367462612023CEMIP promotes small cell lung cancer proliferation by activation of glutamine metabolism via FBXW7/c-Myc-dependent axis.2
368494602023CEMIP, acting as a scaffold protein for bridging GRAF1 and MIB1, promotes colorectal cancer metastasis via activating CDC42/MAPK pathway.2
369316082023CEMIP-mediated hyaluronan metabolism facilitates SCLC metastasis by activating TLR2/c-Src/ERK1/2 axis.1

Citation

Nikki Ann Evensen ; Cem Kuscu ; Jian Cao

CEMIP (cell migration inducing protein, hyaluronan binding )

Atlas Genet Cytogenet Oncol Haematol. 2013-10-01

Online version: http://atlasgeneticsoncology.org/gene/51053/haematological-explorer/js/css/template-card.css